Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–111 of 111 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NGF Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Sabroxy™ (Oroxylum Indicum Extract) for Improving Cognitive Function in Adults With Mild Memory Concerns

NCT07189754
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Cognitive Dysfunction, Cognitive Disorder, Memory Problems
Interventions
Sabroxy™ (Oroxylum indicum extract), Placebo
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
60 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 19, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS

NCT03799718
View directory record Official record
Conditions
Multiple Sclerosis, Chronic Progressive
Interventions
NurOwn (MSC-NTF cells)
Biological
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Redwood City, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 19, 2026, 10:41 PM EDT
Completed Not applicable Interventional

Understanding How Cognitive Remediation Works

NCT01683539
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Chronic Mental Disorder, Major Depression, Bipolar Disorder
Interventions
The Thinking Skills for Work Program, The Cognitive Skills for Work Program
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 19, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Results available

Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

NCT01258387
View directory record Official record
Conditions
Heart Failure
Interventions
Glial growth factor 2/ Neuregulin 1β3, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 19, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Results available

To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

NCT02542605
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo, PACAP-38 Challenge Agent
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 19, 2026, 10:41 PM EDT
Completed Phase 4 Interventional Results available

Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms

NCT01457573
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
Tamsulosin, Solifenacin
Drug
Lead sponsor
Timothy Boone, MD, PhD
Other
Eligibility
45 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 19, 2026, 10:41 PM EDT
Not listed Phase 3 Interventional

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

NCT01050114
View directory record Official record
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 19, 2026, 10:41 PM EDT
Not listed Phase 2 Interventional

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

NCT04163419
View directory record Official record
Conditions
Schwannomatosis, Pain
Interventions
Tanezumab, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 19, 2026, 10:41 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Determine the Safety and Efficacy of NT-501 With MHFM

NCT06397131
View directory record Official record
Conditions
Macular Telangiectasia Type 2
Interventions
NT-501 CNTF Implant
Combination Product
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Walnut Creek, California • Grand Rapids, Michigan • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 19, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

NCT02697773
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 19, 2026, 10:41 PM EDT
Active, not recruiting Phase 1 Interventional

CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS

NCT05306457
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CNS10-NPC-GDNF
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 19, 2026, 10:41 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Biomarkers in Obstructive Sleep Apnea

NCT02325687
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Lumbar Puncture (Standard-of-Care)
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 84 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 19, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AIT-082 Phase 1B Study

NCT00000180
View directory record Official record
Conditions
Memory Disorders
Interventions
AIT-082
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
4
States / cities
San Diego, California • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 19, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)

NCT03071965
View directory record Official record
Conditions
MacTel (Macular Telangiectasia) Type 2
Interventions
Ciliary neurotrophic factor (CNTF), Surgery
Biological · Procedure
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 19, 2026, 10:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

NCT06999733
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
KB801, Placebo
Biological · Drug
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Irvine, California • Pasadena, California • Carmel, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 19, 2026, 10:41 PM EDT